# PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

> **NCT05035381** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 10 (estimated)

## Conditions studied

- MSI-H Advanced Colorectal Cancer

## Interventions

- **DRUG:** Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen

## Key facts

- **NCT ID:** NCT05035381
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035381, "PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05035381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*